Endocrine Abstracts

Pegvisomant (PEG) is effective in acromegaly control and exerts a positive impact on glucose metabolism. The current study aimed at investigating the effects of 10-years PEG treatment on disease control, pituitary adenoma size, and metabolic profile in patients with acromegaly resistant to somatostatin analogues (SRLs). Twenty-two patients (9 men,13 women, age 45.54 ± 12.83 years) treated with PEG for 10 years, in monotherapy or in combination with SRLs, were included in ...

Pasireotide is a second-line therapy for acromegaly, that allows to obtain disease control in patients previously uncontrolled. However, pasireotide-induced hyperglycemia is of major concern. Currently, few data concerning prolonged use of pasireotide are available. The current retrospective study aimed at investigating the efficacy and safety of long-term pasireotide therapy. Sixteen consecutive patients (5 males, 11 females, age 47 ± 11 years) undergoing pasireotide for...

Sleep apnea (SA) is a common acromegaly comorbidity, influencing patients’ quality of life and mortality risk. Despite its importance, SA frequently remains undiagnosed, and its real prevalence seems to be underestimated. The current observational study aimed at investigating the role of Berlin questionnaire (BQ) and Epworth sleepiness scale (ESS) in assessing the risk of SA in this high-risk population, and to compare the results with an age-and gender-matched health coh...